$AEHR

POSEDEL RHEA J sold $836K of AEHR (indirect holdings)

POSEDEL RHEA J (Director) sold 5,973 indirectly-held shares of AEHR TEST SYSTEMS (AEHR) at $140.00 ($0.84M total) on 2026-08-14.

Original reporting
SEC EDGAR · POSEDEL RHEA J
Published Aug 14, 2026, 9:46 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 9:50 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AEHR
Neutral
medium confidence
Mentioned
$AEHR
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AEHRNeutralLow
01

Why it matters

The disclosed sale provides incremental sentiment information but no new information about AEHR’s business performance, guidance, or risk factors.

02

Market read

Traders may monitor for follow-on insider activity, but this single Form 4 sale is not a standalone catalyst.

03

What to watch

The filing notes the sale was indirect and does not state a 10b5-1 plan; traders may over-interpret intent without knowing tax, diversification, or pre-existing arrangements.

Relevance 5/10Novelty 3/10Timing: Filed on 2026-08-14, reflecting an insider sale executed the same day.

Background

The article is a SEC Form 4 insider transaction disclosure for AEHR, listing the director’s role and the details of an open-market sale.

Company-level read

Ticker impact

$AEHRNeutralMedium confidence
Context

Director POSEDEL RHEA J sold 5,973 shares of AEHR on 2026-08-14 for about $836,220, reported as an indirect open-market sale.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.

Evidence & confidence

The filing discloses the transaction size, price ($140/share), and that it was an open-market sale with no 10b5-1 plan stated. However, insider sales are common and the article provides no new operational, financial, or regulatory catalyst.

Market effects

No clear sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

The sale could be routine liquidity management and does not necessarily signal reduced confidence, especially without any accompanying negative company news.

Key entities

  • AEHR

    AEHR Test Systems, the issuer of the Form 4 insider transaction.

  • POSEDEL RHEA J

    Director of AEHR who sold shares via an indirect open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AEHRMed

AEHR Stock Rides AI Order Wave Amid Volatility

Aehr Test Systems (AEHR) stock rose 13.28% following strong earnings and a positive outlook for semiconductor test demand. The company reported $50M in revenue, $18.8M in quarterly revenue, and a net income of $1.39M. Jefferies initiated coverage with a Buy rating and $175 price target, citing AEHR's role in AI production. The stock has shown volatility, with a recent drop of 9.5-10.5% in a single session. Insiders have sold shares but maintain significant holdings. AEHR is actively presenting a

$AEHRHigh

AEHR Stock Rallies As AI Orders And Wall Street Support Build

Aehr Test Systems (AEHR) stock rose 11.71% due to strong AI-related demand. The company reported $18.8M in revenue with a 35.3% gross margin. Jefferies initiated coverage with a Buy rating and $175 price target, citing AEHR's role in AI chip production. The company has a strong balance sheet and a $22M follow-on order from a major customer.

$AEHRHigh

AEHR Stock Rallies As AI Test Orders And Wall Street Support Grow

Aehr Test Systems (NASDAQ: AEHR) stock rose 11.73% on growing AI test demand. The company secured a $22M follow-on order for AI chip testing equipment. Jefferies initiated coverage with a Buy rating and $175 price target, citing AEHR's unique position in AI production testing. The stock has high volatility, with a strong balance sheet but negative EBIT margins.